Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 1, 2025Pediatric Allergy and ImmunologyOpen Access

Prophylactic monoclonal antibodies against respiratory syncytial virus in early life: An in‐depth review of mechanisms of action, failure factors, and future perspectives

View Full Paper
Ask AI
Bookmark
Share

Authors

CVChristelle Vauloup‐FellousMRMarie‐Anne Rameix‐WeltiVGVincent Gajdos

Discussion

Loading...

Member takes

Overview

Review evaluates monoclonal antibodies' impact on reducing RSV incidence in infants, highlighting their potential in universal immunization.

Key Points

  • Remarkable reductions in respiratory syncytial virus hospitalizations observed with monoclonal antibody treatments.
  • Palivizumab is a widely used monoclonal antibody for RSV prophylaxis, with emerging alternatives offering longer protection.
  • Assessment involved reviewing evidence from clinical trials and real-world studies on monoclonal antibody efficacy.
  • Future exploration in bispecific antibodies could enhance pediatric infectious disease prevention against RSV.

Cite This Study

Vauloup‐Fellous et al. (2025) studied this question.

synapsesocial.com/papers/69402a652d562116f2901942https://doi.org/10.1111/pai.70257
View Full Paper
Ask AI
Bookmark
Share